INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $758,948 | -7.2% | 24,003 | +19.9% | 0.00% | 0.0% |
| Q2 2023 | $817,639 | +2.9% | 20,025 | -6.2% | 0.00% | 0.0% |
| Q1 2023 | $794,463 | +12.0% | 21,348 | +5.1% | 0.00% | 0.0% |
| Q4 2022 | $709,487 | +67.7% | 20,314 | +167.6% | 0.00% | 0.0% |
| Q3 2022 | $423,000 | +8.2% | 7,592 | +0.2% | 0.00% | 0.0% |
| Q2 2022 | $391,000 | -52.7% | 7,577 | -12.4% | 0.00% | -50.0% |
| Q1 2022 | $826,000 | -18.5% | 8,645 | +1.0% | 0.00% | 0.0% |
| Q4 2021 | $1,013,000 | -8.0% | 8,557 | +4.4% | 0.00% | 0.0% |
| Q3 2021 | $1,101,000 | -35.9% | 8,197 | -22.6% | 0.00% | -50.0% |
| Q2 2021 | $1,717,000 | +80.0% | 10,586 | -11.0% | 0.00% | +100.0% |
| Q1 2021 | $954,000 | +58.5% | 11,897 | +7.3% | 0.00% | 0.0% |
| Q4 2020 | $602,000 | +215.2% | 11,087 | +15.2% | 0.00% | +100.0% |
| Q3 2020 | $191,000 | -8.2% | 9,621 | -2.9% | 0.00% | 0.0% |
| Q2 2020 | $208,000 | +23.8% | 9,912 | -26.8% | 0.00% | 0.0% |
| Q1 2020 | $168,000 | – | 13,539 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |